{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesofensine","verification":{"valid":true,"entries":7,"head":"e4290d4d3ab918d840585537b1c1b2ae73959c2c67cb662fca0d789c4187ffaf"},"count":7,"sources":[{"id":"s1","type":"pubmed","pmid":"18950853","external_id":"18950853","url":"https://pubmed.ncbi.nlm.nih.gov/18950853/","title":"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","quote":"After 24 weeks, the mean weight loss produced by diet and placebo was 2.0% (SE 0.60). Tesofensine 0.25 mg, 0.5 mg, and 1.0 mg and diet induced a mean weight loss of 4.5% (0.87), 9.2% (0.91), and 10.6% (0.84), respectively, greater than diet and placebo (p<0.0001).","summary":"Astrup et al., Lancet 2008: the single phase II efficacy trial. 203 obese patients across five Danish centres, 24 weeks, 79% completion, registered as NCT00394667. This is where every number quoted about tesofensine comes from. The 9.2% is the margin over placebo, not the total.","author":"Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM","publisher":"The Lancet","date":"2008","tag":"Randomised controlled trial (phase II)","accessed_at":"2026-08-05T09:39:19.492Z","prev":"genesis","hash":"c802c10deb0d6450154567eb4b849e213903954a6bcafb98326696966bab988f"},{"id":"s2","type":"pubmed","pmid":"23561987","external_id":"23561987","url":"https://pubmed.ncbi.nlm.nih.gov/23561987/","title":"Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","quote":"Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.","summary":"The Lancet 2013;381(9873):1167. A formal notice from the journal attached to the 2008 trial, linked from that paper’s PubMed record in both directions. Not a retraction, and not nothing: the one trial supporting this compound carries a journal-issued caution. Most pages quoting the 9.2% omit it.","publisher":"The Lancet","date":"2013","tag":"Journal expression of concern","accessed_at":"2026-08-05T09:39:19.492Z","prev":"c802c10deb0d6450154567eb4b849e213903954a6bcafb98326696966bab988f","hash":"fc11a9341be37f8910e8c99c923a0de19d69a43b3b7ba73c0e18cf75f75df295"},{"id":"s3","type":"pubmed","pmid":"18950853","external_id":"18950853-safety","url":"https://pubmed.ncbi.nlm.nih.gov/18950853/","title":"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","quote":"After 24 weeks, tesofensine 0.25 mg and 0.5 mg showed no significant increases in systolic or diastolic blood pressure compared with placebo, whereas heart rate was increased by 7.4 beats per min in the tesofensine 0.5 mg group (p=0.0001).","summary":"Tesofensine phase II trial — adverse events and cardiovascular findings. The same trial’s safety result, quoted separately because it is the finding that shaped the compound’s regulatory fate. 7.4 extra beats per minute at the dose that produced the headline weight loss, in a population already carrying cardiovascular risk.","author":"Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM","publisher":"The Lancet","date":"2008","tag":"Safety outcome","accessed_at":"2026-08-05T09:39:19.492Z","prev":"fc11a9341be37f8910e8c99c923a0de19d69a43b3b7ba73c0e18cf75f75df295","hash":"8ba30c38d9298c2667000416710a89916bc75bc06b6c04197a763aef56f35d2f"},{"id":"s4","type":"pubmed","pmid":"20479765","external_id":"20479765","url":"https://pubmed.ncbi.nlm.nih.gov/20479765/","title":"The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men","quote":"No significant effect of TE on total 24-h EE could be demonstrated compared with PL, but higher energy expenditure was observed during the night period (4.6%; P<0.05) when adjusted for changes in body composition.","summary":"Sjödin et al., Int J Obes 2010: 32 men, respiration chamber, two weeks. The one study built to measure whether tesofensine raises energy expenditure. It does not, meaningfully — the effect was confined to the night period. \"Boosts metabolism\" is the most common claim made for this compound and this is the study that tested it.","author":"Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A","publisher":"International Journal of Obesity","date":"2010","tag":"Mechanism study","accessed_at":"2026-08-05T09:39:19.492Z","prev":"8ba30c38d9298c2667000416710a89916bc75bc06b6c04197a763aef56f35d2f","hash":"51d637d4416d26a01e1bd9c134e4a8b8dff0e90c332b3a76b6ef4677d394fd24"},{"id":"s5","type":"pubmed","pmid":"20479765","external_id":"20479765-appetite","url":"https://pubmed.ncbi.nlm.nih.gov/20479765/","title":"The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men","quote":"TE also induced higher ratings of satiety and fullness and concomitantly lower prospective food intake than placebo.","summary":"Tesofensine and appetite: satiety and prospective food intake. The positive half of the same mechanism study. Appetite changed substantially while energy expenditure did not, which is the honest description of how tesofensine produces weight loss: it makes people want to eat less.","author":"Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A","publisher":"International Journal of Obesity","date":"2010","tag":"Mechanism study","accessed_at":"2026-08-05T09:39:19.492Z","prev":"51d637d4416d26a01e1bd9c134e4a8b8dff0e90c332b3a76b6ef4677d394fd24","hash":"b3e4bda2e3cad8d7472ad64dcd4dba2396281389040a0d72814146985e35ba3e"},{"id":"s6","type":"pubmed","pmid":"18950853","external_id":"18950853-interpretation","url":"https://pubmed.ncbi.nlm.nih.gov/18950853/","title":"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","quote":"Our results suggest that tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved drugs. However, these findings of efficacy and safety need confirmation in phase III trials.","summary":"Tesofensine phase II trial — the authors’ own interpretation. The trial authors’ conclusion, including the second sentence. No phase III obesity trial has been published in the eighteen years since. The hedge is part of the finding.","author":"Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM","publisher":"The Lancet","date":"2008","tag":"Authors’ conclusion","accessed_at":"2026-08-05T09:39:19.492Z","prev":"b3e4bda2e3cad8d7472ad64dcd4dba2396281389040a0d72814146985e35ba3e","hash":"3028b7454430525a93d0dab55fe4c0a238bdb2e5cbfacb920784a4943ae376e3"},{"id":"s7","type":"pubmed","pmid":"19824222","external_id":"19824222","url":"https://pubmed.ncbi.nlm.nih.gov/19824222/","title":"[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]","quote":"Tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved anti-obesity drugs. Findings of safety and efficacy of 0.5 mg Tesofensine need confirmation in phase III trials.","summary":"The effect of tesofensine on body weight and body composition in obese subjects — secondary publication. Nielsen et al., Ugeskr Laeger 2009: the Danish secondary publication of the same 203-patient trial. Useful because it shows the literature is one trial reported more than once, not several trials agreeing.","author":"Nielsen AL, Larsen TM, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Astrup A","publisher":"Ugeskrift for Laeger","date":"2009","tag":"Secondary publication of the same trial","accessed_at":"2026-08-05T09:39:19.492Z","prev":"3028b7454430525a93d0dab55fe4c0a238bdb2e5cbfacb920784a4943ae376e3","hash":"e4290d4d3ab918d840585537b1c1b2ae73959c2c67cb662fca0d789c4187ffaf"}]}